Comparative Evaluation of the Effects of Oral Anti-hyperglycemic Agents and an Ayurvedic Hepatoprotective Agent in a Rat Model of Non-alcoholic Fatty Liver Disease (NAFLD). [PDF]
Kalra SSS +3 more
europepmc +1 more source
Effectiveness and Safety of a Fixed-Dose Combination of Dapagliflozin and Vildagliptin in the Treatment of Type 2 Diabetes Mellitus: A Retrospective Study. [PDF]
Sanghvi A, Warrier S.
europepmc +1 more source
Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). [PDF]
Xiong W, Li Y, Huang J, He G, Sun J.
europepmc +1 more source
Correction: Fabrication of novel vildagliptin loaded ZnO nanoparticles for anti diabetic activity. [PDF]
Samad A +12 more
europepmc +1 more source
Association between daily dose of dipeptidyl peptidase-4 inhibitors and change in glycated hemoglobin in patients with type 2 diabetes: interpretation of mixed-effects machine-learning models using electronic medical records. [PDF]
Hayakawa T +5 more
europepmc +1 more source
Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus. [PDF]
Aloke C +4 more
europepmc +1 more source
Association Between DPPs-4 Inhibitors and Bullous Pemphigoid: Reporting Odds Ratio Analysis Using EudraVigilance Database. [PDF]
Pedrero AC, Aldea-Perona A.
europepmc +1 more source
Efficacy and Safety of Vildagliptin Versus Other Dipeptidyl Peptidase 4 (DPP-4) Inhibitors in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. [PDF]
Selvaraj V.
europepmc +1 more source
CD26 as a potential therapeutic target for lung adenocarcinoma. [PDF]
Jungraithmayr W +10 more
europepmc +1 more source
Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid in an Elderly Woman With Type 2 Diabetes Mellitus: A Case Report. [PDF]
Roa Alvarez G +4 more
europepmc +1 more source

